Recent News

• 01.12.2026 - Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
• 01.12.2026 - Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
• 01.05.2026 - Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
• 01.05.2026 - Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
• 12.17.2025 - Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
• 12.17.2025 - Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
• 11.05.2025 - Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
• 11.05.2025 - Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

Recent Filings

• 01.07.2026 - 8-K Current report
• 12.15.2025 - 8-K Current report
• 11.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.15.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities